Bellevue Life Sciences Acquisition - Tradeable Rights - Feb 2028 Long Term Debt

The latest long-term debt for BLACR is $280K as of June 2026. That compares with $20K in the prior-year period — up 1248.8% year over year. Investors often review this figure alongside Bellevue Life Sciences Acquisition - Tradeable Rights - Feb 2028's historical trend and sector peers before judging valuation or financial health.

Over the past year, BLACR's long-term debt moved from $20K to $280K — a 1248.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Bellevue Life Sciences Acquisition - Tradeable Rights - Feb 2028's operating scale or balance-sheet position.

A long-term debt figure of $280K for BLACR is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting BLACR's long-term debt ($280K), review year-over-year change from $20K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.